搜索范围
T2577
应用筛选条件
关键词:'T2577'
显示 1-30 #N/A 313 条结果 关于 "T2577" 范围 论文
Chao Chen et al.
Journal of Zhejiang University. Science. B, 24(8), 698-710 (2023-08-08)
To explore the role of forkhead box protein O1 (FOXO1) in the progression of glioblastoma multiforme (GBM) and related drug resistance, we deciphered the roles of FOXO1 and miR-506 in proliferation, apoptosis, migration, invasion, autophagy, and temozolomide (TMZ) sensitivity in
Jin Lan et al.
FEBS letters, 588(18), 3333-3339 (2014-08-01)
Understanding the resistance of glioma cells to chemotherapy has been an enormous challenge. In particular, mechanisms by which tumor cells acquire resistance to chemotherapy under hypoxic conditions are not fully understood. In this study, we have found that miR-497 is
Franziska Briest et al.
Oncotarget, 6(10), 8185-8199 (2015-03-24)
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous tumors that need to be molecularly defined to obtain novel therapeutic options. Forkheadbox protein M1 (FOXM1) is a crucial transcription factor in neoplastic cells and has been associated with differentiation and proliferation. We found
Terri S Armstrong et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(32), 4076-4084 (2013-10-09)
Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma. Tests of neurocognitive function (NCF) and symptoms (using the MD Anderson Symptom Inventory-Brain Tumor module;
Ming-De Fan et al.
Experimental and therapeutic medicine, 20(2), 802-809 (2020-08-09)
Temozolomide (TMZ) resistance is a complication of treatment of glioma, and new strategies are urgently required to overcome chemoresistance in glioma cells. In the present study, it was demonstrated that tripartite motif-containing 31 (TRIM31) was abnormally upregulated in glioma tissues
Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells.
Bryn Nelson
Cancer cytopathology, 121(2), 55-56 (2013-02-15)
Zuzana Tatar et al.
Cancer treatment reviews, 39(2), 125-135 (2012-07-24)
Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma. Later, TMZ proved its efficacy in the treatment of melanoma. Multiple publications have demonstrated the benefit of TMZ in
Ku-Chung Chen et al.
PloS one, 14(12), e0225913-e0225913 (2019-12-06)
Temozolomide (TMZ) is a first-line alkylating agent for glioblastoma multiforme (GBM). Clarifying the mechanisms inducing TMZ insensitivity may be helpful in improving its therapeutic effectiveness against GBM. Insulin-like growth factor (IGF)-1 signaling and micro (mi)RNAs are relevant in mediating GBM
Modulation of GABAA receptor signaling increases neurogenesis and suppresses anxiety through NFATc4.
Giorgia Quadrato et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(25), 8630-8645 (2014-06-21)
Correlative evidence suggests that GABAergic signaling plays an important role in the regulation of activity-dependent hippocampal neurogenesis and emotional behavior in adult mice. However, whether these are causally linked at the molecular level remains elusive. Nuclear factor of activated T
Tim C Chang et al.
Lab on a chip, 14(23), 4540-4551 (2014-10-03)
There is a critical unmet need to tailor chemotherapies to individual patients. Personalized approaches could lower treatment toxicity, improve the patient's quality of life, and ultimately reduce mortality. However, existing models of drug activity (based on tumor cells in culture
M Carmen Lafita-Navarro et al.
PLoS genetics, 16(11), e1009117-e1009117 (2020-11-18)
Glioblastoma is the most common and aggressive type of cancer in the brain; its poor prognosis is often marked by reoccurrence due to resistance to the chemotherapeutic agent temozolomide, which is triggered by an increase in the expression of DNA
Dennis J Pelletier et al.
Journal of chemical information and modeling, 47(3), 1196-1205 (2007-04-13)
The identification of phospholipidosis (PPL) during preclinical testing in animals is a recognized problem in the pharmaceutical industry. Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process.
Annalisa Lena et al.
Journal of translational medicine, 7, 13-13 (2009-02-07)
High grade gliomas are one of the most difficult cancers to treat and despite surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is poor. Resistance to temozolomide is the major barrier to effective therapy. Alternative therapeutic approaches have
Kamariah Ibrahim et al.
International journal of molecular medicine, 46(2), 685-699 (2020-05-30)
Glioblastoma multiforme (GBM) is an aggressive type of brain tumour that commonly exhibits resistance to treatment. The tumour is highly heterogenous and complex kinomic alterations have been reported leading to dysregulation of signalling pathways. The present study aimed to investigate
Li-Han Sun et al.
International journal of molecular sciences, 24(3) (2023-02-12)
An escapable (ES)/inescapable stress (IS) paradigm was used to study whether behavioral control and repeated footshock stressors may affect adult neurogenesis and related cognitive function. Male stressed mice having behavioral control (ES) had a short-term escalation in dorsal dentate gyrus
Qionghua Shen et al.
Cancer letters, 506, 142-151 (2021-02-28)
Metastasized cancer cells have an increased resistance to therapies leading to a drastic decrease in patient survival rates. However, our understanding of the cause for this enhanced resistance is lacking. In this study, we report that physically tight confinement during
Satoshi Tanaka et al.
Journal of neurosurgery, 121(4), 818-826 (2014-08-12)
Methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) has been reported to be a good prognostic factor for patients with glioblastoma multiforme (GBM). To determine whether the absolute value of MGMT messenger RNA (mRNA) might be a prognostic factor and useful for predicting
Shao-Ming Wang et al.
Cell death discovery, 7(1), 8-8 (2021-01-14)
Glioblastoma (GBM) is the most aggressive brain tumor and relapses after chemo- or radiotherapy in a short time. The anticancer drug temozolamide (TMZ) is commonly used for GBM treatment, but glioma stem-like cells (GSCs) often lead to drug resistance and
Judith Wienke et al.
Cancer cell, 42(2), 283-300 (2024-01-06)
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options with less side effects. Since novel and improved immunotherapies may fill this need, we dissect the immunoregulatory interactions in neuroblastoma by single-cell RNA-sequencing of
Tamar Canello et al.
PloS one, 9(12), e113854-e113854 (2014-12-03)
Silencing of O(6)-methylguanine-DNA-methyltransferase (MGMT) in tumors, mainly through promoter methylation, correlates with a better therapeutic response and with increased survival. Therefore, it is conceivable to consider MGMT as a potential therapeutic target for the treatment of cancers. Our previous results
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma.
Fabro, et al.
Frontiers in Oncology, 12, 1012236-1012236 (2022)
Nicolai Stransky et al.
Cancers, 14(24) (2022-12-24)
Reportedly, the intermediate-conductance Ca2+-activated potassium channel KCa3.1 contributes to the invasion of glioma cells into healthy brain tissue and resistance to temozolomide and ionizing radiation. Therefore, KCa3.1 has been proposed as a potential target in glioma therapy. The aim of
T C Hirst et al.
British journal of cancer, 108(1), 64-71 (2013-01-17)
Malignant glioma is an aggressive tumour commonly associated with a dismal outcome despite optimal surgical and radio-chemotherapy. Since 2005 temozolomide has been established as first-line chemotherapy. We investigate the role of in vivo glioma models in predicting clinical efficacy. We
Jeffrey J Roix et al.
PloS one, 9(8), e101708-e101708 (2014-08-06)
Approved drugs target approximately 400 different mechanisms of action, of which as few as 60 are currently used as anti-cancer therapies. Given that on average it takes 10-15 years for a new cancer therapeutic to be approved, and the recent
Kuo-Hao Ho et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 17(3), 1212-1227 (2020-01-10)
DNA damage-inducible transcript 4 (DDIT4) is known to participate in various cancers, including glioblastoma multiforme (GBM). However, contradictory roles of DDIT4 exist in inducing cell death and possessing anti-apoptotic functions against cancer progression. Herein, we investigated DDIT4 signaling in GBM
Silvia Paukovcekova et al.
Cancers, 12(12) (2020-12-19)
Combining low-dose chemotherapies is a strategy for designing less toxic and more potent childhood cancer treatments. We examined the effects of combining the novel thiosemicarbazones, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), or its analog, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), with the standard chemotherapies, celecoxib (CX), etoposide
Jeffrey J Olson et al.
Journal of neuro-oncology, 118(3), 501-555 (2014-04-18)
What is the impact of cytotoxic chemotherapy on disease control and survival in the adult patient with progressive glioblastoma? This recommendation applies to adults patients with progressive glioblastoma. Temozolomide is recommended as superior to procarbazine in patients with first relapse
Liyen Katrina Kan et al.
Purinergic signalling, 16(3), 327-336 (2020-06-26)
Gliomas, the most common primary brain cancer, are highly infiltrative and extremely difficult to treat. Despite advancements, current treatment is limited, with patients surviving for a median of 14-15 months post-diagnosis. Previous research has demonstrated the upregulation of a purinergic receptor
Lucio Tentori et al.
Blood, 99(6), 2241-2244 (2002-03-06)
Temozolomide (TZM) is a DNA-methylating agent that has recently been introduced into various clinical trials for treatment of solid or hematologic neoplasias, including brain lymphomas. In the current study, we have investigated whether the antitumor activity of TZM could be
Kelly Burrell et al.
Cancer research, 74(14), 3727-3739 (2014-05-14)
Glioblastoma multiforme (GBM) is characterized by a pathogenic vasculature that drives aggressive local invasion. Recent work suggests that GBM cells recruit bone marrow-derived progenitor cells (BMDC) to facilitate recurrence after radiotherapy, but how this may be achieved is unclear. In
1/11